BRPI0407097A - Antagonista do casr - Google Patents

Antagonista do casr

Info

Publication number
BRPI0407097A
BRPI0407097A BR0407097-6A BRPI0407097A BRPI0407097A BR PI0407097 A BRPI0407097 A BR PI0407097A BR PI0407097 A BRPI0407097 A BR PI0407097A BR PI0407097 A BRPI0407097 A BR PI0407097A
Authority
BR
Brazil
Prior art keywords
compound
antagonist
casr
casr antagonist
calcium
Prior art date
Application number
BR0407097-6A
Other languages
English (en)
Inventor
Yuko Shinagawa
Teruhiko Inoue
Toshihiro Kiguchi
Taku Ikenogami
Naoki Ogawa
Kenji Fukuda
Takashi Nakagawa
Masanori Shindo
Yuki Soejima
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of BRPI0407097A publication Critical patent/BRPI0407097A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)

Abstract

"ANTAGONISTA DO CaSR". A presente invenção refere-se a um composto representado pela seguinte fórmula (1), um sal farmaceuticamente aceitável deste ou uma forma oticamente ativa deste: em que cada símbolo é como definido no relatório descritivo. Um composto tendo uma ação antagonística do receptor sensível ao cálcio, uma composição farmacêutica que compreende o composto, particularmente um antagonista receptor de cálcio e uma droga terapêutica para a osteoporose são fornecidos.
BR0407097-6A 2003-04-23 2004-04-23 Antagonista do casr BRPI0407097A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003119131 2003-04-23
PCT/JP2004/005886 WO2004094362A1 (ja) 2003-04-23 2004-04-23 CaSRアンタゴニスト

Publications (1)

Publication Number Publication Date
BRPI0407097A true BRPI0407097A (pt) 2006-01-24

Family

ID=33308093

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0407097-6A BRPI0407097A (pt) 2003-04-23 2004-04-23 Antagonista do casr

Country Status (30)

Country Link
US (4) US7304174B2 (pt)
EP (3) EP2189439A3 (pt)
JP (1) JP3751312B2 (pt)
KR (1) KR100696927B1 (pt)
CN (2) CN101723921A (pt)
AR (1) AR044075A1 (pt)
AT (1) ATE452121T1 (pt)
AU (1) AU2004232604C1 (pt)
BR (1) BRPI0407097A (pt)
CA (1) CA2513738C (pt)
CL (1) CL2004000868A1 (pt)
CO (1) CO5640091A2 (pt)
CY (1) CY1109880T1 (pt)
DE (1) DE602004024668D1 (pt)
DK (1) DK1619180T3 (pt)
ES (1) ES2337576T3 (pt)
HR (1) HRP20100042T1 (pt)
IL (1) IL169575A (pt)
MX (1) MXPA05007609A (pt)
MY (1) MY138734A (pt)
NO (1) NO20054868L (pt)
NZ (1) NZ541188A (pt)
PE (1) PE20050460A1 (pt)
PL (1) PL1619180T3 (pt)
PT (1) PT1619180E (pt)
RU (1) RU2315036C2 (pt)
SI (1) SI1619180T1 (pt)
TW (1) TWI329628B (pt)
WO (1) WO2004094362A1 (pt)
ZA (1) ZA200505587B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
CA2527203C (en) * 2003-05-28 2010-08-17 Japan Tobacco Inc. Casr antagonist
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US20070155819A1 (en) * 2004-02-06 2007-07-05 Marquis Robert W Jr Calcilytic compounds
WO2007124465A2 (en) * 2006-04-20 2007-11-01 Amgen Inc. Stable emulsion formulations
CA2681582C (en) 2007-03-30 2015-07-14 Amgen Inc. Methods of treating bowel disorders
CA2726610C (en) * 2008-06-05 2015-05-05 Asahi Kasei Pharma Corporation Sulfonamide compounds and use thereof
RU2478616C2 (ru) 2008-12-24 2013-04-10 Дайити Санкио Компани, Лимитед Циклические аминосоединения
NZ593676A (en) 2008-12-24 2012-06-29 Daiichi Sankyo Co Ltd Calcium-sensing receptor antagonists
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
WO2010103429A1 (en) * 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists
SG174564A1 (en) * 2009-03-26 2011-10-28 Japan Tobacco Inc Process for producing carboxylic acid compound
WO2010113860A1 (ja) * 2009-03-31 2010-10-07 第一三共株式会社 ビフェニル－環状アミン化合物
JP2012528084A (ja) 2009-05-27 2012-11-12 レオ ファーマ アクティーゼルスカブ 新規のカルシウム感知受容体調節化合物およびその医薬用途
WO2010136037A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2012069421A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
RU2013128981A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении чувствительных к кальцию рецепторов
WO2012069402A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Substituted cyclopentyl - azines as casr- active compounds
CN103270018A (zh) 2010-11-26 2013-08-28 利奥制药有限公司 钙敏感受体激活化合物
GB201113538D0 (en) * 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
HK1211916A1 (en) * 2012-08-27 2016-06-03 Lupin Atlantis Holdings Sa Arylalkylamine compounds as calcium sensing receptor modulators
CA3027290A1 (en) 2016-06-13 2017-12-21 Syneurx International (Taiwan) Corp. Use of lithium benzoate for treating central nervous system disorders
WO2021115272A1 (zh) * 2019-12-09 2021-06-17 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物及其应用
CN116648243A (zh) * 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂
MX2023003129A (es) * 2020-09-18 2023-08-04 Calcilytix Therapeutics Inc Compuestos trifenil-calciliticos para el tratamiento de hipocalcemia autosomica dominante tipo 1 (adh1).
WO2024220796A1 (en) 2023-04-21 2024-10-24 Calcilytix Therapeutics, Inc. Treatment of hypoparathyroidism using triphenyl calcilytic compounds

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE633760A (pt) * 1963-06-18
DD207203A1 (de) * 1982-06-21 1984-02-22 Peter Meisel Verfahren zur herstellung von epoxypropylethern
DE3743265A1 (de) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg Neue ammoniumverbindungen, ihre herstellung und verwendung
US5276008A (en) * 1990-08-09 1994-01-04 Bayer Aktiengesellschaft Substituted 4,5-diamino-1,2,4-triazol-3-(thi)ones
DE69233586T2 (de) * 1991-08-23 2006-09-28 NPS Pharmaceuticals, Inc., Salt Lake City Kalzium-Rezeptor aktive Verbindungen
SG99290A1 (en) 1996-04-09 2003-10-27 Nps Pharma Inc Calcilytic compounds
US6818660B2 (en) 1996-04-09 2004-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
EP0827746B1 (en) * 1996-09-05 2002-04-03 Eli Lilly And Company Carbazole analogues as selective beta3 adrenergic agonists
UY24949A1 (es) 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos
AR014975A1 (es) * 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento
US20020052509A1 (en) 1998-04-08 2002-05-02 Smithkline Beecham Corporation Calcilytic compounds and method of use
PE20000415A1 (es) 1998-04-08 2000-05-21 Smithkline Beecham Corp Compuestos calciliticos
US6334338B1 (en) 1998-07-02 2002-01-01 Lucent Technologies Inc. Sol gel process of making a fiber preform with removal of oxide particles
WO2000009491A1 (en) 1998-08-12 2000-02-24 Smithkline Beecham Corporation Calcilytic compounds
JP2002522499A (ja) 1998-08-12 2002-07-23 スミスクライン・ビーチャム・コーポレイション カルシウム分解化合物
PL347432A1 (en) * 1998-10-23 2002-04-08 Hoffmann La Roche Bicyclic nitrogen heterocycles
PE20001456A1 (es) 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
MXPA02002129A (es) * 1999-08-27 2002-09-18 Procter & Gamble Componentes de formulacion de accion rapida, composiciones y metodos para lavanderia que los emplean.
IL152925A (en) 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
AR030684A1 (es) 2000-01-24 2003-09-03 Smithkline Beecham Corp Compuestos calciliticos, uso de dichos compuestos en la manufactura de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos
US20030018203A1 (en) 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
US6867299B2 (en) * 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
HUP0300758A2 (hu) 2000-07-21 2003-08-28 Smithkline Beecham Corp. Kalcilitikus vegyületek és alkalmazásuk kalciumreceptor antagonistákként
US6916956B2 (en) 2000-08-11 2005-07-12 Japan Tobacco, Inc. Calcium receptor antagonist
WO2002034204A2 (en) 2000-10-25 2002-05-02 Smithkline Beecham Corporation Calcilytic compounds
US20040009980A1 (en) 2000-10-25 2004-01-15 Pradip Bhatnagar Calcilytic compounds
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
US6864267B2 (en) 2001-07-16 2005-03-08 Smithkline Beecham Corporation Calcilytic compounds
CA2527203C (en) * 2003-05-28 2010-08-17 Japan Tobacco Inc. Casr antagonist

Also Published As

Publication number Publication date
HK1083096A1 (en) 2006-06-23
EP1619180B1 (en) 2009-12-16
PT1619180E (pt) 2009-12-29
AR044075A1 (es) 2005-08-24
US20120301552A1 (en) 2012-11-29
PL1619180T3 (pl) 2010-05-31
IL169575A (en) 2011-07-31
DK1619180T3 (da) 2010-03-29
CN1741984A (zh) 2006-03-01
EP1619180A1 (en) 2006-01-25
PE20050460A1 (es) 2005-07-08
CL2004000868A1 (es) 2005-01-21
JP3751312B2 (ja) 2006-03-01
HRP20100042T1 (hr) 2010-02-28
ZA200505587B (en) 2006-09-27
CN101723921A (zh) 2010-06-09
AU2004232604A8 (en) 2004-11-04
KR100696927B1 (ko) 2007-03-20
AU2004232604B2 (en) 2007-09-13
EP2189439A2 (en) 2010-05-26
MXPA05007609A (es) 2005-09-30
US20090326058A1 (en) 2009-12-31
KR20050094047A (ko) 2005-09-26
DE602004024668D1 (de) 2010-01-28
AU2004232604C1 (en) 2008-06-05
NO20054868L (no) 2005-12-20
TW200505823A (en) 2005-02-16
RU2315036C2 (ru) 2008-01-20
EP2189439A3 (en) 2011-05-04
TWI329628B (en) 2010-09-01
NO20054868D0 (no) 2005-10-21
US20080255042A1 (en) 2008-10-16
US20050032796A1 (en) 2005-02-10
EP2308828A2 (en) 2011-04-13
WO2004094362A1 (ja) 2004-11-04
ES2337576T3 (es) 2010-04-27
CA2513738A1 (en) 2004-11-04
NZ541188A (en) 2008-01-31
AU2004232604A1 (en) 2004-11-04
EP1619180A4 (en) 2006-05-24
CO5640091A2 (es) 2006-05-31
RU2005123985A (ru) 2006-01-27
EP2308828A3 (en) 2013-05-22
IL169575A0 (en) 2007-07-04
MY138734A (en) 2009-07-31
US7304174B2 (en) 2007-12-04
ATE452121T1 (de) 2010-01-15
CA2513738C (en) 2010-04-06
AU2004232604B8 (en) 2004-11-04
SI1619180T1 (sl) 2010-04-30
CY1109880T1 (el) 2014-09-10
JPWO2004094362A1 (ja) 2006-07-13
CN100577633C (zh) 2010-01-06

Similar Documents

Publication Publication Date Title
CY1109880T1 (el) ΑΝΤΑΓΩΝΙΣΤΗΣ CaSR
BRPI0417771A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóides
BRPI0511504A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
BRPI0417947A (pt) composto, composição farmacêutica, fabricação de um medicamento para o uso no tratamento e/ou prevenção de um metabólico distúrbio, e, formulação farmacêutica
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
BR0312729A (pt) Novos derivados de indol-3-enxofre
BR122019017036B8 (pt) compostos de arilamidas substituídas por tetrazol, usos dos referidos compostos e composição farmacêutica
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
CY1109860T1 (el) Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις
EP1630157A4 (en) ANTAGONIST OF CASR
SE0401342D0 (sv) Therapeutic compounds
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
MA28706B1 (fr) Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques
BRPI0706992C1 (pt) composto de fórmula (i) e formulação farmacêutica
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BR0313727A (pt) Derivados de isoquinolina como inibidores de metaloproteinase da matriz
CL2004001347A1 (es) Compuestos derivados de 4-[(imidazol-4il)etinil]-piridina sustituidos; procedimientos de preparacion; composicion farmaceutica; y su uso en la elaboracion de un medicamento util para el tratamiento o prevencion de trastornos inducidos por el receptor
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
BRPI0511778A (pt) derivados da naftalina úteis como ligantes do receptor 3 da histamina
BRPI0410044A (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
SE0402635D0 (sv) Chemical compounds
SE0303480D0 (sv) Benzofuranes
BR0103048A (pt) Derivados de n-triazolilmetil-piperazina como antagonistas de receptores de neuroquinina
BRPI0519351A2 (pt) medicamentos para o tratamento ou prevenÇço de doenÇas fibràticas
BRPI0409217A (pt) derivados e análogos antimicrobianos da [3.1.0]bicicloexilfeniloxazolidinona

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.